| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ixekizumab |
| Brand | Taltz® |
| Indication | For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies |
| Assessment Process | |
| Rapid review commissioned | 16/10/2018 |
| Rapid review completed | 19/11/2018 |
| Rapid review outcome | Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013
